Search This Blog

Thursday, June 11, 2020

DarioHealth up big on remote patient monitoring deals

Thinly traded nano cap DarioHealth (NASDAQ:DRIO) has inked the first of two remote patient monitoring (RPM) contracts involving its turnkey RPM solution that integrates its open platform, application technology and the DarioEngage coaching platform.
The company does not disclose the size of the deal, but investors appear impressed. Shares are up 80% premarket on increased volume.
https://seekingalpha.com/news/3582277-dariohealth-up-big-on-remote-patient-monitoring-deals

Tenet Healthcare to update on business June 16

Tenet Healthcare (THC -5.7%) will host a conference call and webcast on Tuesday, June 16, at 10:00 am ET to update investors on its operations.
Current Q2 consensus is a loss/share of ($0.98) on revenues of $3.75B.
Current 2020 consensus is EPS of $1.18 on revenues of $17.34B.
https://seekingalpha.com/news/3582312-tenet-healthcare-to-update-on-business-june-16

AIM ImmunoTech files provisional patent for the use of Ampligen in COVID-19

AIM ImmunoTech (NYSEMKT:AIM) has filed a provisional patent application for the use of its experimental drug Ampligen as a potential early-onset therapy for the treatment of COVID-19 induced chronic fatigue, which shows similarities to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
https://seekingalpha.com/news/3582287-aim-immunotech-files-provisional-patent-for-use-of-ampligen-in-covidminus-19

Exelixis launches late-stage study of Cabometyx combo in lung cancer

Exelixis (NASDAQ:EXEL) initiates a Phase 3 clinical trial, CONTACT-01, evaluating the combination of Cabometyx (cabozantinib) and Roche’s Tecentriq (atezolizumab) in patients with metastatic non-small cell lung cancer who have been previously treated with an immune checkpoint inhibitor nd platinum-based chemo.
The primary endpoint of the 350-subject study is overall survival.
The company plans two additional Phase 3s, in metastatic castration-resistant prostate cancer and renal cell carcinoma, under its clinical trial collaboration with Roche.
https://seekingalpha.com/news/3582292-exelixis-launches-late-stage-study-of-cabometyx-combo-in-lung-cancer

Twist Bio expands offering of synthetic coronavirus controls

Twist Bioscience (TWST -3.3%) has added four new synthetic SARS-CoV-2 controls to its offering that include new variants of the coronavirus.
It launched its first two controls in March.
Controls are used in the development and validation of diagnostic tests.
https://seekingalpha.com/news/3582295-twist-bio-expands-offering-of-synthetic-coronavirus-controls

White House, GOP push relief talks to late July – CNBC

The Trump administration and Republican negotiators are not planning to hold formal talks on a fourth COVID-19 stimulus package until after Congress returns from recess in late July, CNBC reports, citing senior administration officials and senior GOP aides.
The two houses are scheduled to return to D.C. on July 21, some 10 days before some of the programs in the CARES Act, such as enhanced unemployment insurance, are set to end.
GOP lawmakers and the administrators now have some positive data on unemployment and data showing that a good chunk of previous stimulus funds remain unspent.
“We want to be careful at this point, seeing how much money is in the economy,” Mnuchin testified to the Senate committee on Small Business on Wednesday. “A lot of the money is still not in it.”
The administration estimates that more than half of funds from the last three stimulus programs remains “unobligated,” or not yet spent.
President Trump has said there will be another round of stimulus.
https://seekingalpha.com/news/3582297-white-house-gop-push-relief-talks-to-late-july-cnbc

Moderna moves forward with Phase 3 study of COVID-19 vaccine

The company has finalized its Phase 3 study protocol, and the trial of mRNA-1273 on about 30K subjects is expected to begin next month.
The primary endpoint of the randomized, placebo-controlled trial will be prevention of symptomatic COVID-19 disease.
Collaborating with Lonza, Moderna (NASDAQ:MRNA) remains on track to be able to deliver about 500M doses per year, and maybe up to 1B doses per year beginning in 2021.
Shares are down 0.95% premarket. Updating at 8:11 AM ET: Shares have now moved into the green, up 2.4% premarket.
https://seekingalpha.com/news/3582229-moderna-moves-forward-phase-3-study-of-covidminus-19-vaccine